Japanese journal of clinical oncology
-
Jpn. J. Clin. Oncol. · Jul 2009
Comparative StudyRetrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Patients with multiple myeloma (MM) achieving high-quality responses, defined as a complete response (CR) and a very good partial response (VGPR) after transplant, benefit from high-dose therapy followed by autologous stem cell transplantation (ASCT). Induction pre-transplantation treatment with vincristine, doxorubicin and dexamethasone (VAD) is currently being replaced by new targeted agents with high anti-myeloma activity. The use of these novel agents may increase the CR + VGPR rate before ASCT, which may improve post-transplantation responses and survival. ⋯ The results of this retrospective comparison of bortezomib-containing regimens with the VAD as induction treatment prior to ASCT for MM provided a demonstration of the superiority of bortezomib therapy in terms of achieving a high-quality response. However, survivals following ASCT did not differ according to the induction regimens.
-
Jpn. J. Clin. Oncol. · Jul 2009
Risk factors for severe Dysphagia after concurrent chemoradiotherapy for head and neck cancers.
The aim of this study was to investigate the risk factors for dysphagia induced by chemoradiotherapy for head and neck cancers. ⋯ Larger radiation portal field was associated with severe dysphagia induced by chemoradiotherapy.